Article ID Journal Published Year Pages File Type
8829002 Progrès en Urologie - FMC 2018 4 Pages PDF
Abstract
Immune checkpoint inhibitors have recently become an important step for the treatment of multiple cancers. The two main drugs have the ability to reactivate the immune system against tumor cells. They can also be responsible for a lot of side effects, among which few endocrine related side effects. With anti-CTLA4, studies showed mostly hypophysitis and with anti-PD-(L)1 blockade thyroid dysfunction was mainly observed. In addition, some type 1 diabetes mellitus have been observed.
Related Topics
Health Sciences Medicine and Dentistry Urology
Authors
, ,